Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

3(60.0%)

Phase 1

2(40.0%)

5Total

Phase 2(3)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT03343756Terminated

HepaStem Long-Term Safety Registry

Role: lead

NCT04229901Phase 2Terminated

Study to Evaluate the Efficacy and Safety of HepaStem in Patients With Acute on Chronic Liver Failure (ACLF)

Role: lead

NCT01765283Phase 1Completed

Safety Study of HepaStem for the Treatment of Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN)

Role: lead

NCT02489292Phase 2Completed

Study to Evaluate the Efficacy of HepaStem in Urea Cycle Disorders Paediatric Patients (HEP002)

Role: lead

NCT03963921Phase 1Completed

Safety and Tolerability of HepaStem in Patients With Cirrhotic and Pre-cirrhotic NASH Patients

Role: lead

NCT02946554Phase 2Completed

Phase II Safety Study of 2 Dose Regimens of HepaStem in Patients With ACLF

Role: lead

NCT02051049Completed

Long-term Safety Follow-up Study of Patients Having Received HepaStem (SAF001)

Role: lead

All 7 trials loaded